Modeling Tumor Dynamics and Overall Survival in Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib

被引:12
|
作者
Suleiman, Ahmed Abbas [1 ]
Frechen, Sebastian [1 ]
Scheffler, Matthias [2 ]
Zander, Thomas [2 ]
Kahraman, Deniz [3 ]
Kobe, Carsten [3 ]
Wolf, JRgen [2 ]
Nogova, Lucia [2 ]
Fuhr, Uwe [1 ]
机构
[1] Univ Hosp Cologne, Dept Pharmacol, Clin Pharmacol Unit, D-50931 Cologne, Germany
[2] Univ Hosp Cologne, Ctr Integrated Oncol Cologne, Dept Internal Med 1, Lung Canc Grp Cologne, D-50931 Cologne, Germany
[3] Univ Hosp Cologne, Ctr Integrated Oncol Cologne Bonn, Dept Nucl Med, D-50931 Cologne, Germany
关键词
Modeling; NSCLC; PET; Survival; Erlotinib; POSITRON-EMISSION-TOMOGRAPHY; PHASE-II; SIZE; PET; OPPORTUNITIES; PREDICTION; ONCOLOGY; EVALUATE; DESIGN; RECIST;
D O I
10.1097/JTO.0000000000000330
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Pharmacostatistical models can quantify different relationships and improve decision making in personalized medicine and drug development. Our objectives were to develop models describing non-small-cell lung cancer (NSCLC) dynamics during first-line treatment with erlotinib, and survival of the cohort. Methods: Data from patients with advanced NSCLC (n = 39) treated first-line with erlotinib (150 mg/day) were analyzed using nonlinear mixed effects modeling. Exposure-driven disease-drug models were built to describe tumor metabolic and proliferative dynamics evaluated by positron emission tomography (PET) using 2'-deoxy-2'-[F-18] fluoro-D-glucose (FDG) and 3'-[F-18] fluoro-3'-deoxy-L-thymidine (FLT), respectively, at baseline, weeks 1 and 6 after starting erlotinib treatment. A parametric time-to-event model was built to describe overall survival (OS). Demographics, histology, mutational, smoking, and baseline performance statuses were tested for their effects on models developed, in addition to tumor dynamics on survival. Results: An exponential relationship described progression, and a concentration-driven drug effect model described erlotinib effect. An activating epidermal growth factor receptor (EGFR) mutation increased the drug effect as assessed using FDG-PET by 2.19-fold (95% confidence interval [CI]: 1.35-4.44). An exponential distribution described the times-to-death distribution. Baseline FDG uptake (p=0.0005; hazard ratio [HR] = 1.26 for every unit increase, 95% CI: 1.13-1.42) and relative change in FDG uptake after 1 week of treatment (p=0.0073; HR=0.84 for every 10% drop, 95% CI: 0.71-0.91) were significant OS predictors irrespective of the EGFR mutational status. FLT-PET was statistically less significant than FDG-PET for OS prediction. Conclusion: Models describing tumor dynamics and survival of advanced NSCLC patients first-treated with erlotinib were developed. The impacts of different covariates were quantified.
引用
收藏
页码:84 / 92
页数:9
相关论文
共 50 条
  • [31] A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients
    Ahmed Abbas Suleiman
    Sebastian Frechen
    Matthias Scheffler
    Thomas Zander
    Lucia Nogova
    Martin Kocher
    Ulrich Jaehde
    Jürgen Wolf
    Uwe Fuhr
    [J]. The AAPS Journal, 2015, 17 : 1483 - 1491
  • [32] Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer
    Rossi, Antonio
    La Salvia, Anna
    Di Maio, Massimo
    [J]. EXPERT REVIEW OF RESPIRATORY MEDICINE, 2017, 11 (03) : 171 - 180
  • [33] Erlotinib in patients with advanced non-small-cell lung cancer: a meta-analysis
    Gao, Hui
    Ding, Xin
    Wei, Dong
    Cheng, Peng
    Su, Xiaomei
    Liu, Huanyi
    Aziz, Fahad
    Wang, Daoyuan
    Zhang, Tao
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (02) : 129 - 144
  • [34] Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer
    Hotta, Katsuyuki
    Kiura, Katsuyuki
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (07) : 991 - 997
  • [35] CT findings in non-small-cell lung cancer patients treated with gefitinib or erlotinib
    Na, Im Il
    Choe, Du Hwan
    Kim, Cheol Hyeon
    Park, Sun Hoo
    Park, Jong Heon
    Lee, Jae Cheol
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2012, 8 (02) : 247 - 253
  • [36] EFFECTIVENESS OF ERLOTINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER AFTER FAILURE OF GEFITINIB
    Saito, Haruhiro
    Murakami, Shuji
    Honda, Takeshi
    Kondo, Tetsuro
    Oshita, Fumihiro
    Noda, Kazumasa
    Yamada, Kouzo
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 26 - 26
  • [37] A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer
    Goldberg, Sarah B.
    Supko, Jeffrey G.
    Neal, Joel W.
    Muzikansky, Alona
    Digumarthy, Subba
    Fidias, Panos
    Temel, Jennifer S.
    Heist, Rebecca S.
    Shaw, Alice T.
    McCarthy, Patricia O.
    Lynch, Thomas J.
    Sharma, Sreenath
    Settleman, Jeffrey E.
    Sequist, Lecia V.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) : 1602 - 1608
  • [38] Modeling tumor and treated lung volume influences in the irradiation of non-small-cell lung cancer patients
    Abratt, RP
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (02): : 481 - 485
  • [39] The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC)
    Groen, H.
    Arrieta, O. G.
    Riska, H.
    Horwood, K.
    Mali, P.
    Reck, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer
    Reinmuth, Niels
    Reck, Martin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1647 - +